Biomedical Systems Expert Shares Insight On The Future Of QT In Clinical Trials
ST. LOUIS--(BUSINESS WIRE)--Timothy Callahan, Ph.D., chief medical officer of Biomedical Systems, a premier, global provider of centralized diagnostic services, spoke on “Cardiac Safety in the Post E14 Era” at a recent seminar in Suzhou, China.
That information and his recent article in Applied Clinical Trials shed light on the future of QT in clinical trials in response to the FDA’s indication that the thorough QT trial (TQT) will need to be replaced. The ICH guidance document E14, originally endorsed in 2005, covers the TQT trial.
Help employers find you! Check out all the jobs and post your resume.
That information and his recent article in Applied Clinical Trials shed light on the future of QT in clinical trials in response to the FDA’s indication that the thorough QT trial (TQT) will need to be replaced. The ICH guidance document E14, originally endorsed in 2005, covers the TQT trial.
Help employers find you! Check out all the jobs and post your resume.